Saturday, August 15, 2026 Never miss a recall or a rule change Go Pro · $20/mo →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
InjectablesHugel Debuts Thechaum Signature with Reduced CrosslinkertodayBusiness & M&AEvolus Tops Q2 Revenue Forecast, Raises 2026 Outlook3 days agoInjectablesGLP-1 Boom Exposed Filler Limitations—Here's WhytodayDevices & TechUltherapy PRIME Clears FDA for Knee Skin Laxity3 days agoInjectablesGalderma Chief: Start GLP-1 Patients on Skin Care FirstyesterdayInjectablesEvolus' Injectable Platform Is Becoming Its Real Moat2 days agoDevices & TechAlma Launches TitaniumLift™ Multi-Depth RF ProtocolyesterdayDevices & TechInMode Q2 Revenue Beats at $95.6M on Device Demand2 days agoBusiness & M&ABeauty Health Q2 Earnings: Device Demand SteadyyesterdayMarketHugel Posts Record H1 Revenue on Overseas Toxin Surge2 days agoBusiness & M&AEstablishment Labs Raises 2026 Revenue GuidanceyesterdayMarketMedytox Q2 Sales Up 11%, Operating Profit Down 25%2 days ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Injectables

Hugel Debuts Thechaum Signature with Reduced Crosslinker

Hugel's new HA filler uses less crosslinker. What the rheology shift means for your practice.

Image: Inside MedSpa
1-YEAR MOVE
+15% −13%
ABBV ▲11.6%
1-year price move by ticker
TickerCompany1-year change
ABBVAbbVie (Allergan Aesthetics)+11.6%

Hugel has launched Thechaum Signature, a hyaluronic acid filler formulated with reduced crosslinker density compared to standard HA offerings. The approach aims to deliver a softer, more malleable product that maintains longevity while improving natural feel and ease of injection—a rheological trade-off that appeals to practitioners seeking less resistance during placement and patients prioritizing a subtle aesthetic.

Hugel's new filler uses less crosslinker for softer feel and easier injection.

Reduced crosslinking typically correlates with faster resorption and softer tissue integration, making Thechaum Signature a potential play for first-time filler patients or those seeking frequent touch-ups over sustained volume. Hugel's positioning reflects broader market consolidation around customized crosslink profiles: Galderma's Emervel and Restylane lines, Allergan's Voluma and Vollure, and Revance's Nuvo all target specific rheological niches. Your filler mix and patient preference data should inform whether Thechaum Signature fits your portfolio—particularly if you're seeking a softer midface option or testing Korean aesthetics brands.

Source: original report ↗

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $20/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://insidemedspa.com/article/hugel-thechaum-signature-crosslinker-innovation/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa Pro

    By the time it's news, it's too late.

    The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

    Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.
    The twice-a-week intelligence brief Go Pro · $20/mo